Semaglutide injection (Wegovy; Novo Nordisk) now has an additional indication for the reduction of major adverse cardiovascular events in adults with established CVD and either overweight or obesity, ...
The analyses included 3389 adults with a body mass index of at least 30.0kg/m2 who initiated semaglutide or liraglutide for obesity or type 2 diabetes. (HealthDay News) — For patients with obesity ...
Weight reduction at one year linked to medication active agent, dosage, treatment indication, persistence of coverage. HealthDay News — For patients with obesity receiving semaglutide or liraglutide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results